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yet determined the beneﬁt of medical expulsion therapy for stones in different ureteral locations.
Objective: The aim of the study was to evaluate tamsulosin as adjunctive therapy to extracorporeal shock
wave lithotripsy (SWL) in terms of pain clearance of stones in the upper, middle, and lower ureter.
Methods: Between June 2008 and July 2011, patients with a solitary ureteral stone that was Z6 mm up
to 15 mm and located in the upper, middle, or lower ureter undergoing SWL were evaluated. The patients
were randomly allocated to a conservative treatment (group 1) and a tamsulosin treatment group
(group 2). Administration of the drug was started immediately after SWL and was continued for a
maximum of 28 days. Patients were evaluated for stone clearance, time to stone clearance, and number of
SWL sessions. The pain intensity was evaluated by visual analog scale.
Results: There were 64 patients in the control group and 59 in the tamsulosin group. The average stone sizes
were 10.70 (3.20) mm and 11.40 (3.01) mm (P ¼ 0.24). Group 1 and group 2 received 2507 (984) and 2759
(775) shock waves (P ¼ 0.86), 1.53 (0.8) and 1.49 (0.75) sessions (P ¼ 0.85), respectively. Mean visual analog
scale scores and times to clearance were 3.81 (2.74) and 2.73 (2.28) (P ¼ 0.00) and 12.59 (8.63) days and 8.34
(7.60) days (P ¼ 0.00), respectively, for all stones in groups 1 and 2. Only the clearance time of upper ureteral
stones between groups showed statistical signiﬁcance (13.54 [8.32] days vs 7.10 [6.40] days; P ¼ 0.00).
Conclusions: Tamsulosin may help in the treatment of all ureteral stones after SWL, particularly stones in the
upper ureter, with a shorter time to clearance and less need for analgesic drugs.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Urolithiasis affects 4% to 15% of the world population, and the
incidence of this disease is increasing.1 Ureteral stone disease is one
of the important issues that an urologist encounters in emergency
clinical settings. Although shock wave lithotripsy (SWL) is accepted
in many institutions as the ﬁrst-line treatment option for patients
with ureteral stones, observation can be preferred for ureteric
calculi measuring a maximum of 5 mm, in the absence of infection
or renal insufﬁciency.1 In the stone migration process, ureteral
activity is modulated by the sympathetic nervous system.2 In
several studies, the density of a1-D-adrenergic receptors in the
ureteral smooth muscle cells is greater than that of other adrenergicier Inc.
, OS, Maltepe U¨niversitesi
addesi, No. 39, PK:34843,
glu).
Open access under CC BY-NCreceptors.3 In this context, the a1-adrenergic antagonists are able to
inhibit basal tone and peristaltic frequency, dilating the ureteral
lumen and facilitating stone passage.4
These pharmacologic agents, shown to facilitate ureteral stone
expulsion and reduce total analgesic drug use, have been used for
medical expulsion therapy (MET).5–7
Among them, tamsulosin was used in several recent studies,
but the results of studies are variable, and most of them were
carried out on patients with lower ureteral and renal
calculi.8–10
To our knowledge, no study has deﬁned the contribution of
MET after SWL separately for upper, middle, and lower ureteral
stones in terms of pain and clearance time. Thus, we planned to
use tamsulosin, as adjunctive therapy, to evaluate its role in
treating stones in different ureteral locations.Materials and Methods
Between June 2008 and July 2011, patients with a solitary
ureteral stone that was Z6 mm up to 15 mm and located in the-ND license.
Table II
Table I








Sex distribution, male:female 51:13 47:12 0.99
Age, y 42.19 (13.17) 44.66 (13.25 0.32
Stone size, mm 10.70 (3.20) 11.40 (3.01) 0.24
Clinical
No. of SWL sessions 1.53 (0.8) 1.49 (0.75) 0.85
Mean shock waves/session 2507 (984) 2759 (775) 0.86
Pain, VAS score 3.81 (2.74) 2.73 (2.28) 0.00
No. of days to clearance 12.59 (8.63) 8.34 (7.60) 0.00
SWL, shock wave lithotripsy; VAS, visual analog scale.
n Continuous variables are presented in mean (SD).
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Written informed consent was obtained from each participant,
and the institutional review board approved our study. The
assessment of stone size and location was performed by plain
x-ray of the kidneys, ureters, and bladder (KUB) and/or ultrasound
imaging. The exclusion criteria were age younger o18 years;
weight o50 kg or 4100 kg; severe skeletal malformation;
pregnancy; aortic and/or renal artery aneurysm; a history of drug
or alcohol abuse; long-term use of drugs such as antidepressants,
histamine blockers, and anxiolytics and allergy to one of the study
medications; concomitant treatment with calcium antagonists
and/or an a1-adrenergic antagonist; concomitant renal stones;
previous unsuccessful attempts at SWL; elevated serum creati-
nine (42 mg/dL); urinary tract infection; diabetes; peptic ulcers;
history of spontaneous stone expulsion; hypotension; coagulo-
pathy; urinary congenital anomalies; or previous nephroureteral
surgery. The patients were randomly allocated to conservative
treatment (group 1) and tamsulosin treatment (group 2) using the
coin toss method in order to choose the nontreatment and
Tamsulosin arms. All patients were evaluated before treatment
with KUB and renal ultrasonography. Before lithotripsy, clinical
(history and brief physical examination) and laboratory (complete
blood count, urine culture, renal function, coagulation parameters
screening, and pregnancy test) examinations were conducted.
Additional KUB and ultrasonography were performed just before
lithotripsy. Drug administration was started immediately after
SWL and was continued for a maximum of 28 days or until an
alternative treatment was started. The patients who were not
stone free at this examination were excluded from the study and
underwent additional treatment. A total of 123 patients met these
requirements. Group 1 (64 patients) received standard medical
therapy alone and was used as the control group. Group 2 (59
patients) was assigned to receive our standard medical therapy in
association with 0.4 mg tamsulosin once daily. Our standard
medical therapy after SWL was 75 mg diclofenac injected intra-
muscularly on demand. A gastroprotective therapy (40 mg
pantoprozol once daily) was given to every patient. After dis-
charge, all patients were instructed to drink a minimum of 2 L of
water daily and were asked to complete a diary about post-
discharge pain, stone expulsion, use of analgesic drugs, and side
effects of medical therapy. Patients were evaluated for stone
clearance, time to stone clearance, and number of SWL sessions.
The pain intensity was evaluated with the visual analog scale
(VAS). The patients were requested to deﬁne pain in a scale of 1 to
10 by comparing it with the most severe pain the patients could
imagine (0, no pain, to 10, the most severe pain imagined).
Follow-up included clinical examination, urinalysis with culture
and sensitivity testing as required, renal KUB, and/or ultrasono-
graphy, repeated 5 days after each lithotripsy session.
The ﬁnal examination was performed with ultrasonography or
helical computed tomography at day 28 to conﬁrm stone-free status.
All SWL treatments were performed with Storz Medical AG Modulith
Slk (Ta¨gerwilen, Switzerland) with both ultrasonic and ﬂuoroscopic
focusing. The mean intensity and number of shock waves after the
ﬁrst SWL session were 18.5 kV (range, 6–19) and 3140 (range, 2700–
3600). Statistical analysis was performed using SPSS software, version
16.0 (SPSS Inc, Chicago, Illinois). The differences between groups
1 and 2 were tested using the t test, Mann-Whitney U test, w2 test,
and Fisher exact test. P o 0.05 was considered statistically signiﬁcant.Comparison of mean (SD) pain scores according to ureteral stone location.
Stone Location Group 1 (N ¼ 64) Group 2 (N ¼ 59) P
Upper ureter (n ¼ 57) 4.00 (2.58) (n ¼ 28) 2.90 (2.19) (n ¼ 29) 0.69
Middle ureter (n ¼ 28) 3.00 (3.91) (n ¼ 12) 2.38 (2.42) (n ¼ 16) 0.56
Lower ureter (n ¼ 38) 4.00 (2.71) (n ¼ 24) 2.79 (2.42) (n ¼ 14) 0.12
VAS, visual analog scale.Results
Demographic and clinical characteristics of all patients are
summarized in Table I. The data for the 123 patients who
completed follow-up without dropping out met the criteria; 64in group 1 and 59 in group 2. The average stone sizes were 10.70
(3.20) mm and 11.40 (3.01) mm (P ¼ 0.24). The patients in the
2 groups underwent SWL treatment. Groups 1 and 2 received 2507
(984) and 2759 (775) shock waves (P ¼ 0.86) and underwent 1.53
(0.8) and 1.49 (0.75) sessions (P ¼ 0.85), respectively. Statistically
signiﬁcant differences in terms of pain score (3.81 [2.74] vs 2.73
[2.28], P ¼ 0.00) (Table II) and clearance time (12.59 [8.63] days
vs 8.34 [7.60] days, P ¼ 0.00) (Table III) for all stones were found
between groups 1 and 2. The difference in VAS score between the
groups was not statistically signiﬁcant if the stones were classiﬁed
according to upper, middle, and lower ureteral locations (Table II).
Only the clearance time of upper ureteral stones between groups
showed statistical signiﬁcance (13.54 [8.32] vs 7.10 [6.40],
P ¼ 0.00) (Table III). The mean cumulative diclofenac dose
was 375 mg (5 injections) per patient in group 1 and 225 mg
(3 injections) per patient in group 2, with a statistically signiﬁcant
difference between the 2 groups (P ¼ 0.00). No relevant side
effects in connection with tamsulosin that would cause the
medication to discontinued were observed during follow-up.Discussion
The ﬁrst-line treatment options for patients with upper uret-
eral calculi with o1.5 cm in size are extracorporeal SWL and
ﬂexible ureterorenoscopic lithotripsy.1 Fragment expulsion after
renal SWL is similar to spontaneous discharge of the stone itself.
The narrowest part of the ureter is the ureterovesical junction,
and spasm, edema, or infection of this location may impede stone
passage.1,6 The pain associated with the obstructing stone is
called renal or ureteral colic and is a visceral pain that refers to
the somatic region corresponding to the spinal segment of the
sympathetic efferent of the ureter.11 Many studies suggest that
edema, infection, spasm, and ureteral peristalsis may be improved
by an appropriate medical therapy. Furthermore, a1-adrenergic
antagonists may decrease ureteral peristaltic frequency, reducing
spasm in ureteral smooth muscle, and an increase in the rate of
ﬂuid transport follows these changes.4,6
Table III
Comparison of stone clearance times according to ureteral location.
Stone Location No. (SD) Days to Clearance P
Group 1 (N ¼ 64) Group 2 (N ¼ 59)
Upper ureter (n ¼ 57) 13.54 (8.32) (n ¼ 28) 7.10 (6.40) (n ¼ 29) 0.00
Middle ureter (n ¼ 28) 10.75 (8.20) (n ¼ 12) 9.25 (9.95) (n ¼ 16) 0.56
Lower ureter (n ¼ 38) 12.42 (9.38) (n ¼ 24) 9.86 (6.94) (n ¼ 14) 0.42
B. Cakıroglu et al. / Current Therapeutic Research 74 (2013) 33–35 35In this study, tamsulosin was chosen from among the available
a-blockers because it is a combined a1A and a1-D selective
adrenergic antagonist, considering studies that demonstrated
the existence of a1A and a1-D adrenoceptor subtypes in the
smooth muscle cells of the human ureter.4 Tamsulosin increases
the urine bolus and intraureteral pressure above the stone. It also
decreases peristalsis below the ureter, which consequently lowers
intraureteral pressure in association with the decrease in basal
and micturition pressure, even at the bladder neck; thus, it
increases the chance of stone expulsion. Furthermore, the phasic
peristaltic contractions also decrease in the obstructed ureter,
which leads to an eventual decrease in the painful stimulus.6
Several studies in the past decade investigated the issue.
In a randomized, nonplacebo-controlled study enrolling
patients with lower ureteral stones undergoing SWL, a signiﬁcantly
greater success rate was obtained in patients receiving tamsulosin
0.4 mg/d (70.8% vs 33.3%; P o 0.019) with minimal side effects.12
Another study reported an improved success rate with tamsu-
losin in 60 patients with renal and ureteral stones undergoing
SWL (96.6% vs 79.3%; P o 0.04).9 In contrast to these reports, a
study with 64 patients receiving SWL for lower ureteral stones
found a statistically similar success rate in patients with or
without tamsulosin (66.6% vs 58.1%; P 4 0.05).13
It is also worth noting that among the drugs used for MET,
only corticosteroids seem to induce more rapid stone expulsion
compared with tamsulosin.14.
With regard to the present study, we found a favorable effect
of tamsulosin in clearance time of fragments after SWL, regardless
of ureteral position of the initial stone. When the stones were
classiﬁed according to ureteral location, the clearance time for
only upper ureteral stone fragments was signiﬁcantly shorter
compared with the control group.
Besides decreasing clearance time, investigators also suggest
that a1-blockers potentiate the spasmoanalgesic action of drugs
used in standard treatment.15
The use of tamsulosin as a spasmolytic drug during episodes of
ureteral colic due to calculi in the ureterovesical junction also
seems beneﬁcial. Several authors reported an increased stone
expulsion rate with a decrease in stone clearance time and the
need for hospitalization particularly, with good control of pain.6
The number of colic episodes and the needs for analgesic drugs
seems to be signiﬁcantly lower with the use of tamsulosin.13 In
2 recent studies evaluating clearance time and decrease in pain
for only upper ureteral stones, the authors reported unanimously
that passage of fragments was faster, although a signiﬁcant
advantage in terms of decreasing pain associated with tamsulosin
was not certain in 1 of these 2 series.16,17
In parallel with the previously mentioned reports, VAS scores
in our patients using tamsulosin after SWL were signiﬁcantly
lower compared with the control group, regardless of stone
location, although the difference between groups was not statis-
tically signiﬁcant when the stones were classiﬁed according to
ureteral location. However, to ensure such signiﬁcance, the
number of groups for each ureteral location was limited in ourseries. Last, the adverse effects of tamsulosin were dizziness in
2 patients and nausea in 6 patients, which was tolerable and
required no additional treatment.Conclusions
Tamsulosin helps in the treatment of stones after SWL,
particularly stones in the upper ureter, with a shorter clearance
time and less need for analgesic drugs. Larger comprehensive
series for stones in different ureteral locations may demonstrate
signiﬁcant beneﬁts of tamsulosin after SWL.
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